Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Tolvaptan (TLV) in Korean patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

Trial Profile

Safety and Efficacy of Tolvaptan (TLV) in Korean patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Hyponatraemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2018 New trial record
    • 09 Apr 2018 Primary endpoint (The average serum sodium concentrations on days 18) has not been met, according to results published in the Journal of Korean Medical Science.
    • 09 Apr 2018 Primary endpoint (The average serum sodium concentrations on days 0 and 4) has been met, according to results published in the Journal of Korean Medical Science.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top